Common statin tested to block liver cancer in cirrhosis patients
NCT ID NCT02968810
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This phase II trial tests whether simvastatin, a common cholesterol-lowering drug, can prevent liver cancer in 52 adults with liver cirrhosis. Participants take simvastatin and are monitored with blood tests and imaging to see if cancer-related markers decrease. The goal is to find a low-cost way to reduce cancer risk in this high-risk group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Centro Comprensivo de Cancer de UPR
San Juan, 00927, Puerto Rico
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of Puerto Rico
San Juan, 00936, Puerto Rico
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
simvastatin (a statin drug, typically used to lower cholesterol)
What this could lead to
If it works, this could point toward a way to lower liver cancer risk in people with cirrhosis using a common, inexpensive drug.
What could go wrong
This is a small, early-phase trial (52 people) looking at blood markers, not cancer rates. Statins can cause muscle pain or liver issues, and the benefit is unproven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.